The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada

Health Policy

Volumn 84, Issue 1, 2007, Pages 1-13

  Marshall, Deborah A ^a,b   Willison, Donald J ^a,b   Grootendorst, Paul ^b,c   LeLorier, Jacques ^d   Maclure, Malcolm ^e,f   Kulin, Nathalie A ^a   Sheehy, Odile E ^d   Warren, Leanne ^f   Sykora, Kathy ^g   Rahme, Elham ^h  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF VICTORIA   (Canada)

^f MINISTRY OF HEALTH   (Canada)

^g INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^h HYDRO QUÉBEC   (Canada)

Author keywords

Administrative restrictions; Analgesics; Cox 2 inhibitors; Coxibs; Drug diffusion; Health policy; Limited use policy; Non steroidal anti inflammatory drugs; Special authority

Indexed keywords

ANALGESIC AGENT; CELECOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; VALDECOXIB;

ARTICLE; CANADA; DRUG COST; DRUG FORMULARY; DRUG USE; HEALTH CARE PLANNING; HEALTH CARE POLICY; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS;

EID: 34848839819     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2007.04.010     Document Type: Article

References (37)

1. Drug expenditure in Canada: 1985-2004. Ottawa: Canadian Institute for Health Information; 2005.
2. Drug expenditure in Canada: 1985-2003. Ottawa: Canadian Institute for Health Information; 2004.
3. Morgan S. Drug spending in Canada: recent trends and causes. Medical Care 42 (2004) 635-642
4. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine 343 (2000) 1520-1528
5. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib long-term Arthritis Safety Study. Journal of American Medical Association 284 (2000) 1247-1255
6. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine 345 (2001) 433-442
7. Wright J.M. The double-edged sword of COX-2 selective NSAIDs. Canadian Medical Association Journal 167 (2002) 1131-1137
8. Mamdani M., Juurlink D.N., Lee D.S., Rochon P.A., Kopp A., Naglie G., et al. Cyclo-oxygenase inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363 (2004) 1751-1756
9. Mamdani M., Rochon P., Juurlink D.N., Anderson G.M., Kopp A., Naglie G., et al. Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of Internal Medicine 163 (2003) 481-486
10. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. Journal of American Medical Association 286 (2001) 954-959
11. Ray W.A., Stein C.M., Hall K., Daugherty J.R., and Griffin M.R. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359 (2002) 118-123
12. Oberholzer-Gee F., and Inamdar S.N. Merck's recall of rofecoxib-a strategic perspective. New England Journal of Medicine 351 (2004) 2147-2149
13. Ontario Ministry of Health. Handbook of limited use drug products. 38 ed. Ottawa: Ministry of Health; 2004.
14. BC PharmaCare, http://www.healthservices.gov.bc.ca/pharme/index.html. Special Authority Process Overview. Victoria: British Columbia Ministry of Health; c1995-2005 [updated 2005 October 28; cited 2005 November 29]. Available from: http://www.healthservices.gov.bc.ca/pharme/sa/criteria/sachart.pdf.
15. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs. 4 ed. (2001), WHO, Oslo, Norway
16. Merlo J., Wessling A., and Melander A. Comparison of dose standard units for drug utilisation studies. European Journal of Clinical Pharmacology 50 (1996) 27-30
17. Statistics Canada. Estimates of population by age group and sex, Canada, provinces and territories. CANSIM database [online]. Available from: http://cansim2.statcan.ca/ [accessed 2003 November 11].
18. Brocklebank J.C., and Dickey D.A. SAS System for Forecasting Time Series (1986), SAS Institute, Cary, NC
19. Ostrom C.W. Time series analysis: regression techniques 2 (1990), Sage, Thousand Oaks, CA
20. McDowall D., McCleary R., Meidinger E.E., and Hay R.A. Interrupted time series analysis (1990), Sage, Thousand Oaks, CA
21. Box G.E.P., and Jenkins G.M. Time series analysis: forecasting and control (1976), Holden-Day, Oakland, CA
22. Newey W.K., and West K.D. A simple, positive semi-definite, heteroskedasticity and autocorrelation consistent covariance matrix. Econometrica 55 (1987) 703-708
23. Grimshaw J.M., Thomas R.E., MacLennan G., Fraser C., Ramsay C.R., Vale L., et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technology Assessment 8 (2001) iii-iiiv
24. Dormuth C.R., Maclure M., Bassett K., Jauca C., Whiteside C., and Wright J.M. Effect of periodic letters on evidence-based drug therapy on prescribing behaviour: a randomized trial. Canadian Medical Association Journal 171 9 (2004) 1057-1061
25. Therapeutics Initiative. Celecoxib (Celebrex): is it a breakthrough drug? Therapeutics Letter 1999;31.
26. Therapeutics Initiative. Selective COX-2 inhibitors: are they safer NSAIDs? Therapeutics Letter 2002;39.
27. Therapeutics Initiative. COX-2 inhibitors update: do journal publications tell the full story? Therapeutics Letter 2002;43.
28. ®) withdrawal generates uncertainty about "COX-2s": do product monographs adequately inform? Therapeutics Letter 2004;53.
29. Mamdani M., Rochon P.A., Juurlink D.N., Kopp A., Anderson G.M., Naglie G., et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. British Medical Journal 325 (2002) 624-627
30. Mamdani M., Juurlink D.N., Kopp A., Naglie G., Austin P.C., and Laupacis A. Gastrointestinal bleeding after introduction of COX 2 inhibitors: ecological study. British Medical Journal 328 (2004) 1415-1416
31. Mamdani M., Rochon P., Laupacis A., and Anderson G. Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. Canadian Medical Association Journal 167 (2002) 1125-1126
32. Fischer M.A., Schneeweiss S., Avorn J., and Solomon D.H. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. New England Journal of Medicine 351 (2004) 2187-2194
33. Hamel M.B., and Epstein A.M. Prior-authorization programs for controlling drug spending [comment]. New England Journal of Medicine 351 November (18) (2004) 2156-2158
34. Mamdani M., Warren L., Kopp A., Paterson J.M., Laupacis A., Bassett K., et al. Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. Canadian Medical Association Journal 175 (2006) 1535-1538
35. Cheng H.F., and Harris R.C. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Current Pharmaceutical Design 11 (2005) 1795-1804
36. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine 352 (2005) 1081-1091
37. Barkin R.L., and Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. American Journal of Therapeutics 11 (2004) 124-129